CSIMarket



Worst Performing Stocks In Medical Equipment & Supplies Industry During This Current Quarter Q2 Of 2024



 1 Day   Week  Current Month of June  30 Days 
Current Quarter Q2 of 2024  90 Days    Ytd    12 Months 
 

Shares fell by -1.18% on average, in Medical Equipment & Supplies Industry during this current quarter q2 of 2024.

Here are the Worst performing stocks in Medical Equipment & Supplies Industry.




UTRS

$0.001

$-0.6690 -99.85%
This Quarter Q2 of 2024


UTRS

$0.001

$-0.6690 -99.85%



Minerva Surgical Inc

Minerva Surgical Inc shares went down -99.85% during this current quarter q2 of 2024.


Minerva Surgical Inc*s business model focuses on the development and sale of innovative medical devices specifically designed for gynecological procedures.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 0.009 mill. $ 49.957 mill. $ -33.450 mill. 9 mill. - Y/Y -10.88 %
Market Cap. Revenues TTM Net Income TTM

$ 0.009 mill.


$ 49.957 mill.


$ -33.450 mill.

Employees Shares Outstanding P/E

-


9 mill.


-

Revenue Growth Income Growth

MRQ Y/Y -10.88 %


MRQ Y/Y - %



BTTX

$0.0073

$-0.1967 -96.42%
This Quarter Q2 of 2024


BTTX

$0.0073

$-0.1967 -96.42%



Better Therapeutics Inc

Better Therapeutics Inc shares declined -96.42% during this current quarter q2 of 2024.


Better Therapeutics Inc is a digital therapeutics company that combines evidenced-based clinical interventions with software technology to address chronic diseases. Their business model revolves around developing and delivering prescription software applications to patients, which are meant to be used alongside pharmaceutical therapies. Their aim is to provide personalized and scalable solutions that have the potential to improve health outcomes and reduce healthcare costs.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 0.281 mill. $ - mill. $ -31.573 mill. 39 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 0.281 mill.


$ - mill.


$ -31.573 mill.

Employees Shares Outstanding P/E

-


39 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



LYRA

$0.2588

$-6.1512 -95.96%
This Quarter Q2 of 2024


LYRA

$0.2588

$-6.1512 -95.96%



Lyra Therapeutics Inc

Lyra Therapeutics Inc shares dropped -95.96% during this current quarter q2 of 2024.


Lyra Therapeutics Inc is a biotechnology company that focuses on developing drug-delivery systems for patients with ear, nose, and throat (ENT) diseases. They utilize their proprietary technology, known as XTreo, to precisely deliver therapeutics to targeted areas within the ENT region. Their business model revolves around developing and commercializing these unique drug-delivery solutions to address unmet medical needs in the ENT field.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 14.740 mill. $ 1.423 mill. $ -61.759 mill. 57 mill. - Y/Y 51.53 %
Market Cap. Revenues TTM Net Income TTM

$ 14.740 mill.


$ 1.423 mill.


$ -61.759 mill.

Employees Shares Outstanding P/E

-


57 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 51.53 %


MRQ Y/Y - %



MOTS

$0.0375

$-0.5935 -94.06%
This Quarter Q2 of 2024


MOTS

$0.0375

$-0.5935 -94.06%



Motus Gi Holdings Inc

Motus Gi Holdings Inc stock went down -94.06% during this current quarter q2 of 2024.


Motus Gi Holdings Inc operates as a medical technology company that designs, develops, and commercializes innovative solutions for gastrointestinal endoscopy procedures. Their business model is centered around providing healthcare professionals with advanced imaging and therapeutic technologies to improve patient outcomes and enhance procedural efficiency.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 0.323 mill. $ -441.767 mill. $ -1.891 mill. 9 mill. - Y/Y -41.28 %
Market Cap. Revenues TTM Net Income TTM

$ 0.323 mill.


$ -441.767 mill.


$ -1.891 mill.

Employees Shares Outstanding P/E

-


9 mill.


-

Revenue Growth Income Growth

MRQ Y/Y -41.28 %


MRQ Y/Y - %



NDRA

$0.1299

$-0.9401 -87.86%
This Quarter Q2 of 2024


NDRA

$0.1299

$-0.9401 -87.86%



Endra Life Sciences Inc

Endra Life Sciences Inc shares went down -87.86% during this current quarter q2 of 2024.


Endra Life Sciences Inc*s business model focuses on developing and commercializing advanced imaging technologies and solutions for medical and industrial applications.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 1.404 mill. $ - mill. $ -9.893 mill. 11 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 1.404 mill.


$ - mill.


$ -9.893 mill.

Employees Shares Outstanding P/E

-


11 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



HSDT

$0.996

$-4.8340 -82.92%
This Quarter Q2 of 2024


HSDT

$0.996

$-4.8340 -82.92%



Helius Medical Technologies inc

Helius Medical Technologies Inc stock went down -82.92% during this current quarter q2 of 2024.


Helius Medical Technologies Inc is a company that operates on a subscription-based business model, providing medical technology solutions for the treatment of neurological symptoms and conditions through its proprietary platform known as PoNS. This includes offering PoNS devices and related therapy services to healthcare providers and patients, with an aim to improve patient outcomes and quality of life.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 0.814 mill. $ 0.668 mill. $ -8.872 mill. 1 mill. - Y/Y 21.62 %
Market Cap. Revenues TTM Net Income TTM

$ 0.814 mill.


$ 0.668 mill.


$ -8.872 mill.

Employees Shares Outstanding P/E

-


1 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 21.62 %


MRQ Y/Y - %



AONC

$1.06

$-4.6800 -81.53%
This Quarter Q2 of 2024


AONC

$1.06

$-4.6800 -81.53%



American Oncology Network Inc

American Oncology Network Inc stock declined -81.53% during this current quarter q2 of 2024.


American Oncology Network Inc is a healthcare services company that operates as a physician-led organization, providing comprehensive, community-based oncology care across the United States. They partner with oncologists, hospitals, and practices to deliver high-quality, value-based cancer care while focusing on patient-centric solutions.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 7.980 mill. $ 1,643.524 mill. $ -88.290 mill. 8 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 7.980 mill.


$ 1,643.524 mill.


$ -88.290 mill.

Employees Shares Outstanding P/E

-


8 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



SINT

$5.76

$-19.8400 -77.50%
This Quarter Q2 of 2024


SINT

$5.76

$-19.8400 -77.50%



Sintx Technologies Inc

Sintx Technologies Inc stock declined -77.50% during this current quarter q2 of 2024.


Sintx Technologies Inc is a company that operates under a business model focused on developing and commercializing silicon nitride-based ceramics for various applications.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 198.495 mill. $ 2.775 mill. $ -8.852 mill. 34 mill. - Y/Y 27.46 %
Market Cap. Revenues TTM Net Income TTM

$ 198.495 mill.


$ 2.775 mill.


$ -8.852 mill.

Employees Shares Outstanding P/E

-


34 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 27.46 %


MRQ Y/Y - %



ICU

$4.12

$-13.6800 -76.85%
This Quarter Q2 of 2024


ICU

$4.12

$-13.6800 -76.85%



Seastar Medical Holding Corporation

Seastar Medical Holding Corporation stock declined -76.85% during this current quarter q2 of 2024.


Seastar Medical Holding Corporation*s business model revolves around its operations in the healthcare industry, likely providing medical products or services.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 82.600 mill. $ - mill. $ -42.319 mill. 20 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 82.600 mill.


$ - mill.


$ -42.319 mill.

Employees Shares Outstanding P/E

-


20 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



AFIB

$0.0471

$-0.1331 -73.86%
This Quarter Q2 of 2024


AFIB

$0.0471

$-0.1331 -73.86%



Acutus Medical Inc

Acutus Medical Inc stock declined -73.86% during this current quarter q2 of 2024.


Acutus Medical Inc is a medical technology company that develops and commercializes products for the diagnosis and treatment of cardiac arrhythmias. Their business model focuses on producing innovative and advanced medical devices, such as 3D imaging and mapping systems, to help physicians accurately identify and treat irregular heart rhythms.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 1.399 mill. $ 47.447 mill. $ -66.968 mill. 30 mill. - Y/Y -28.78 %
Market Cap. Revenues TTM Net Income TTM

$ 1.399 mill.


$ 47.447 mill.


$ -66.968 mill.

Employees Shares Outstanding P/E

-


30 mill.


-

Revenue Growth Income Growth

MRQ Y/Y -28.78 %


MRQ Y/Y - %



TIVC

$0.3894

$-0.9206 -70.27%
This Quarter Q2 of 2024


TIVC

$0.3894

$-0.9206 -70.27%



Tivic Health Systems Inc

Tivic Health Systems Inc shares went down -70.27% during this current quarter q2 of 2024.


Tivic Health Systems Inc is a company that operates on a direct-to-consumer business model. They develop and sell at-home medical devices for various health conditions, providing customers with the convenience of accessing healthcare solutions from the comfort of their own homes. By cutting out intermediaries and selling directly to consumers, Tivic Health Systems aims to deliver their products more efficiently and establish a direct relationship with their customers.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 0.463 mill. $ 1.331 mill. $ -9.139 mill. 1 mill. - Y/Y -40.88 %
Market Cap. Revenues TTM Net Income TTM

$ 0.463 mill.


$ 1.331 mill.


$ -9.139 mill.

Employees Shares Outstanding P/E

-


1 mill.


-

Revenue Growth Income Growth

MRQ Y/Y -40.88 %


MRQ Y/Y - %



ATAO

$0.0301

$-0.0589 -66.18%
This Quarter Q2 of 2024


ATAO

$0.0301

$-0.0589 -66.18%



Altair International Corp

Altair International Corp shares dropped -66.18% during this current quarter q2 of 2024.


Altair International Corp is a diversified company with a business model focused on providing a range of products and services. Their offerings span various sectors, including technology, finance, health, and real estate. By leveraging their expertise and network, Altair International Corp aims to capitalize on opportunities and generate revenue through strategic investments, partnerships, and market expansion.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 0.750 mill. $ - mill. $ -1.211 mill. 25 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 0.750 mill.


$ - mill.


$ -1.211 mill.

Employees Shares Outstanding P/E

-


25 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



AMIX

$1.12

$-1.8800 -62.67%
This Quarter Q2 of 2024


AMIX

$1.12

$-1.8800 -62.67%



Autonomix Medical Inc

Autonomix Medical Inc shares went down -62.67% during this current quarter q2 of 2024.





Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 16.454 mill. $ - mill. $ -16.512 mill. 15 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 16.454 mill.


$ - mill.


$ -16.512 mill.

Employees Shares Outstanding P/E

-


15 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



ALUR

$1.06

$-1.7500 -62.28%
This Quarter Q2 of 2024


ALUR

$1.06

$-1.7500 -62.28%



Allurion Technologies Inc

Allurion Technologies Inc stock dropped -62.28% during this current quarter q2 of 2024.


Allurion Technologies Inc is a medical device company that specializes in developing non-surgical solutions for weight loss. Their business model is centered around providing a comprehensive weight loss program that combines their innovative medical device, the Elipse Balloon, with personalized coaching and support. They target individuals seeking a non-invasive and convenient approach to achieving their weight loss goals.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 42.756 mill. $ 29.936 mill. $ -61.118 mill. 40 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 42.756 mill.


$ 29.936 mill.


$ -61.118 mill.

Employees Shares Outstanding P/E

-


40 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



POAI

$1.13

$-1.7200 -60.35%
This Quarter Q2 of 2024


POAI

$1.13

$-1.7200 -60.35%



Predictive Oncology Inc

Predictive Oncology Inc stock went down -60.35% during this current quarter q2 of 2024.


Predictive Oncology Inc is a company that utilizes artificial intelligence to develop predictive models for cancer therapy outcomes. They collaborate with physicians and healthcare providers to apply their models in the clinical setting, aiding in personalized treatment decisions. Their business model revolves around leveraging data analytics and AI technology to offer tailored solutions for the field of oncology.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 4.591 mill. $ 1.960 mill. $ -14.781 mill. 4 mill. - Y/Y 74.93 %
Market Cap. Revenues TTM Net Income TTM

$ 4.591 mill.


$ 1.960 mill.


$ -14.781 mill.

Employees Shares Outstanding P/E

-


4 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 74.93 %


MRQ Y/Y - %



AEMD

$0.675

$-0.9850 -59.34%
This Quarter Q2 of 2024


AEMD

$0.675

$-0.9850 -59.34%



Aethlon Medical Inc

Aethlon Medical Inc shares declined -59.34% during this current quarter q2 of 2024.


Aethlon Medical Inc*s business model revolves around the development and commercialization of innovative therapeutic devices designed to address life-threatening conditions. The company aims to create and market medical solutions that target the removal of disease-causing particles from the circulatory system, with a focus on infectious diseases and cancer.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ - mill. $ - mill. $ -12.630 mill. - mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ - mill.


$ - mill.


$ -12.630 mill.

Employees Shares Outstanding P/E

-


- mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



INBS

$1.89

$-2.7000 -58.82%
This Quarter Q2 of 2024


INBS

$1.89

$-2.7000 -58.82%



Intelligent Bio Solutions Inc

Intelligent Bio Solutions Inc stock declined -58.82% during this current quarter q2 of 2024.


Intelligent Bio Solutions Inc*s business model focuses on providing intelligent solutions in the bio industry.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 3.931 mill. $ 2.516 mill. $ -10.067 mill. 2 mill. - Y/Y 80.24 %
Market Cap. Revenues TTM Net Income TTM

$ 3.931 mill.


$ 2.516 mill.


$ -10.067 mill.

Employees Shares Outstanding P/E

-


2 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 80.24 %


MRQ Y/Y - %



ENDV

$0.0012

$-0.0017 -58.62%
This Quarter Q2 of 2024


ENDV

$0.0012

$-0.0017 -58.62%



Endonovo Therapeutics Inc

Endonovo Therapeutics Inc shares dropped -58.62% during this current quarter q2 of 2024.


Endonovo Therapeutics Inc is a biotechnology company focused on the development of non-invasive electroceuticals for regenerative therapies. Their business model centers around the research, development, and commercialization of their innovative technology that stimulates the body*s natural healing process. With a focus on treating inflammatory conditions and diseases, Endonovo aims to provide advanced, non-pharmaceutical solutions for improved patient outcomes.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 1.621 mill. $ 0.256 mill. $ -4.404 mill. 1,351 mill. - Y/Y -86.13 %
Market Cap. Revenues TTM Net Income TTM

$ 1.621 mill.


$ 0.256 mill.


$ -4.404 mill.

Employees Shares Outstanding P/E

-


1,351 mill.


-

Revenue Growth Income Growth

MRQ Y/Y -86.13 %


MRQ Y/Y - %



COCH

$2.43

$-3.4300 -58.53%
This Quarter Q2 of 2024


COCH

$2.43

$-3.4300 -58.53%



Envoy Medical Inc

Envoy Medical Inc stock declined -58.53% during this current quarter q2 of 2024.


Envoy Medical Inc is a medical device company that develops and sells innovative solutions for individuals with hearing loss, including their flagship product - the Esteem? Hearing Implant. Their business model revolves around designing, manufacturing, and distributing these implantable devices to healthcare providers, ensuring quality patient care and accessibility to those in need of hearing restoration.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 27.253 mill. $ 0.080 mill. $ -1.069 mill. 11 mill. 106.88 Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 27.253 mill.


$ 0.080 mill.


$ -1.069 mill.

Employees Shares Outstanding P/E

-


11 mill.


106.88

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y -76.10 %



SKIN

$1.8

$-2.4500 -57.65%
This Quarter Q2 of 2024


SKIN

$1.8

$-2.4500 -57.65%



The Beauty Health Company

The Beauty Health Company shares declined -57.65% during this current quarter q2 of 2024.


The Beauty Health Company*s business model revolves around selling beauty and health products directly to consumers through a multi-level marketing strategy. Independent distributors are recruited and trained to promote and sell the company*s products to their network, earning commissions and bonuses based on their sales and the sales of their downline. The company focuses on building a loyal customer base while offering opportunities for individuals to earn income through selling and building their own sales teams.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 260.059 mill. $ 392.196 mill. $ -78.510 mill. 144 mill. - Y/Y -5.70 %
Market Cap. Revenues TTM Net Income TTM

$ 260.059 mill.


$ 392.196 mill.


$ -78.510 mill.

Employees Shares Outstanding P/E

-


144 mill.


-

Revenue Growth Income Growth

MRQ Y/Y -5.70 %


MRQ Y/Y - %



PAVM

$0.925

$-1.2350 -57.18%
This Quarter Q2 of 2024


PAVM

$0.925

$-1.2350 -57.18%



Pavmed Inc

Pavmed Inc stock went down -57.18% during this current quarter q2 of 2024.


Pavmed Inc is a medical device company that focuses on developing and commercializing innovative products for various medical fields. The company*s business model revolves around identifying unmet medical needs, acquiring proprietary rights to potential products, and advancing them through development stages to obtain regulatory approvals and market them.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 8.043 mill. $ 3.472 mill. $ -75.561 mill. 9 mill. - Y/Y 90.83 %
Market Cap. Revenues TTM Net Income TTM

$ 8.043 mill.


$ 3.472 mill.


$ -75.561 mill.

Employees Shares Outstanding P/E

-


9 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 90.83 %


MRQ Y/Y - %



STIM

$1.82

$-2.4000 -56.87%
This Quarter Q2 of 2024


STIM

$1.82

$-2.4000 -56.87%



Neuronetics Inc

Neuronetics Inc shares went down -56.87% during this current quarter q2 of 2024.


Neuronetics Inc is a medical device company focused on developing and commercializing non-invasive brain stimulation therapies for psychiatric disorders. Their business model primarily revolves around manufacturing and selling their flagship product, the NeuroStar Advanced Therapy System, which is used for the treatment of major depressive disorder. They generate revenue through the device sales, along with providing support services and maintenance to the healthcare facilities implementing their technology.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 53.639 mill. $ 72.253 mill. $ -27.542 mill. 29 mill. - Y/Y 9.96 %
Market Cap. Revenues TTM Net Income TTM

$ 53.639 mill.


$ 72.253 mill.


$ -27.542 mill.

Employees Shares Outstanding P/E

-


29 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 9.96 %


MRQ Y/Y - %



HSCS

$5.11

$-6.7100 -56.77%
This Quarter Q2 of 2024


HSCS

$5.11

$-6.7100 -56.77%



Heart Test Laboratories Inc

Heart Test Laboratories Inc shares dropped -56.77% during this current quarter q2 of 2024.


Heart Test Laboratories Inc operates as a medical diagnostic company that specializes in heart testing. Their business model revolves around providing innovative and accurate cardiovascular diagnostic tests to healthcare facilities and patients, aimed at early detection and prevention of heart diseases. They achieve this by leveraging advanced technology, collaborating with medical professionals, and offering their services through partnerships with hospitals, clinics, and physicians.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 0.559 mill. $ 0.006 mill. $ -6.090 mill. 0 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 0.559 mill.


$ 0.006 mill.


$ -6.090 mill.

Employees Shares Outstanding P/E

-


0 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



BJDX

$0.3668

$-0.4487 -55.02%
This Quarter Q2 of 2024


BJDX

$0.3668

$-0.4487 -55.02%



Bluejay Diagnostics Inc

Bluejay Diagnostics Inc stock dropped -55.02% during this current quarter q2 of 2024.


Bluejay Diagnostics Inc follows a business model where they develop and manufacture diagnostic tests and medical devices for a variety of health conditions, aiming to provide accurate and efficient solutions to healthcare professionals and patients. They primarily operate by selling their products to hospitals, clinics, and other medical institutions.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 0.405 mill. $ - mill. $ -10.037 mill. 1 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 0.405 mill.


$ - mill.


$ -10.037 mill.

Employees Shares Outstanding P/E

-


1 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



IONM

$0.22

$-0.2600 -54.17%
This Quarter Q2 of 2024


IONM

$0.22

$-0.2600 -54.17%



Assure Holdings Corp

Assure Holdings Corp stock declined -54.17% during this current quarter q2 of 2024.


Assure Holdings Corp is a healthcare company focused on providing neurophysiologic testing services to surgeons and healthcare facilities. They specialize in intraoperative neuromonitoring (IONM) and ensure real-time monitoring and assessment of the nervous system during surgeries. Their business model revolves around offering these specialized services to enhance patient safety and surgical outcomes while working closely with surgeons and hospitals.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 1.540 mill. $ - mill. $ -25.525 mill. 7 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 1.540 mill.


$ - mill.


$ -25.525 mill.

Employees Shares Outstanding P/E

-


7 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



RCEL

$8.02

$-9.0700 -53.07%
This Quarter Q2 of 2024


RCEL

$8.02

$-9.0700 -53.07%



Avita Medical Inc

Avita Medical Inc stock went down -53.07% during this current quarter q2 of 2024.


Avita Medical Inc is a medical technology company that specializes in regenerative medicine. Their business model focuses on developing and commercializing innovative products for the treatment of burns, chronic wounds, and other skin-related conditions.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 203.722 mill. $ 45.403 mill. $ -33.669 mill. 25 mill. - Y/Y 50.08 %
Market Cap. Revenues TTM Net Income TTM

$ 203.722 mill.


$ 45.403 mill.


$ -33.669 mill.

Employees Shares Outstanding P/E

-


25 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 50.08 %


MRQ Y/Y - %



VVOS

$2.13

$-2.3800 -52.77%
This Quarter Q2 of 2024


VVOS

$2.13

$-2.3800 -52.77%



Vivos Therapeutics Inc

Vivos Therapeutics Inc stock dropped -52.77% during this current quarter q2 of 2024.


Vivos Therapeutics Inc employs a business model that focuses on providing innovative solutions for the treatment of breathing-related sleep disorders.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 4.916 mill. $ 12.351 mill. $ -15.643 mill. 2 mill. - Y/Y -23.85 %
Market Cap. Revenues TTM Net Income TTM

$ 4.916 mill.


$ 12.351 mill.


$ -15.643 mill.

Employees Shares Outstanding P/E

-


2 mill.


-

Revenue Growth Income Growth

MRQ Y/Y -23.85 %


MRQ Y/Y - %



NPCE

$6.5

$-6.8800 -51.42%
This Quarter Q2 of 2024


NPCE

$6.5

$-6.8800 -51.42%



Neuropace Inc

Neuropace Inc shares declined -51.42% during this current quarter q2 of 2024.


Neuropace Inc*s business model revolves around the development and commercialization of medical devices for the treatment of neurological disorders, primarily focusing on epilepsy.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 183.854 mill. $ 64.020 mill. $ -35.681 mill. 28 mill. - Y/Y 35.61 %
Market Cap. Revenues TTM Net Income TTM

$ 183.854 mill.


$ 64.020 mill.


$ -35.681 mill.

Employees Shares Outstanding P/E

-


28 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 35.61 %


MRQ Y/Y - %



TMCI

$6.03

$-6.2700 -50.98%
This Quarter Q2 of 2024


TMCI

$6.03

$-6.2700 -50.98%



Treace Medical Concepts Inc

Treace Medical Concepts Inc shares dropped -50.98% during this current quarter q2 of 2024.


Treace Medical Concepts Inc offers innovative surgical solutions primarily for foot and ankle disorders.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 371.222 mill. $ 153.618 mill. $ -62.723 mill. 62 mill. - Y/Y 23.30 %
Market Cap. Revenues TTM Net Income TTM

$ 371.222 mill.


$ 153.618 mill.


$ -62.723 mill.

Employees Shares Outstanding P/E

-


62 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 23.30 %


MRQ Y/Y - %



NUWE

$0.2165

$-0.2238 -50.83%
This Quarter Q2 of 2024


NUWE

$0.2165

$-0.2238 -50.83%



Nuwellis Inc

Nuwellis Inc stock dropped -50.83% during this current quarter q2 of 2024.


Nuwellis Inc.*s business model revolves around developing and commercializing innovative therapeutic solutions, predominantly focusing on fluid management to improve outcomes for patients with critical illnesses. They aim to provide advanced medical devices and solutions to healthcare professionals, addressing the pressing need for better fluid management in critical care settings.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 1.361 mill. $ 8.014 mill. $ -17.093 mill. 6 mill. - Y/Y 1.70 %
Market Cap. Revenues TTM Net Income TTM

$ 1.361 mill.


$ 8.014 mill.


$ -17.093 mill.

Employees Shares Outstanding P/E

-


6 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 1.70 %


MRQ Y/Y - %



CVRX

$11.05

$-10.8200 -49.47%
This Quarter Q2 of 2024


CVRX

$11.05

$-10.8200 -49.47%



Cvrx inc

Cvrx Inc shares declined -49.47% during this current quarter q2 of 2024.


Cvrx Inc. operates on a business model focused on developing medical devices to treat cardiovascular diseases. The company focuses on developing implantable neurostimulation technologies to improve heart function and manage hypertension. They aim to provide innovative solutions that enable better patient outcomes and ultimately revolutionize the field of cardiovascular therapy.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 234.614 mill. $ 41.215 mill. $ -52.011 mill. 21 mill. - Y/Y 27.27 %
Market Cap. Revenues TTM Net Income TTM

$ 234.614 mill.


$ 41.215 mill.


$ -52.011 mill.

Employees Shares Outstanding P/E

-


21 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 27.27 %


MRQ Y/Y - %



TNON

$0.5907

$-0.5293 -47.26%
This Quarter Q2 of 2024


TNON

$0.5907

$-0.5293 -47.26%



Tenon Medical Inc

Tenon Medical Inc stock dropped -47.26% during this current quarter q2 of 2024.


Tenon Medical Inc is a healthcare company that operates on a subscription-based business model, providing medical services and products to subscribers. The company offers a range of medical solutions, including telemedicine consultations, prescription medications, and home delivery of healthcare supplies. Tenon Medical Inc generates revenue through monthly or annual subscription fees, complemented by additional revenue streams from sales of medical products.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 1,344.433 mill. $ 2.397 mill. $ -20.352 mill. 2,276 mill. - Y/Y 353.85 %
Market Cap. Revenues TTM Net Income TTM

$ 1,344.433 mill.


$ 2.397 mill.


$ -20.352 mill.

Employees Shares Outstanding P/E

-


2,276 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 353.85 %


MRQ Y/Y - %



FEMY

$0.955

$-0.8550 -47.24%
This Quarter Q2 of 2024


FEMY

$0.955

$-0.8550 -47.24%



Femasys Inc

Femasys Inc shares declined -47.24% during this current quarter q2 of 2024.


Femasys Inc is a medical technology company that focuses on developing and commercializing innovative solutions for women*s healthcare, specifically in the areas of reproductive and urinary health. Their business model involves designing and manufacturing medical devices, obtaining regulatory approvals, and partnering with healthcare providers and distributors to bring their products to market.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 20.795 mill. $ 1.049 mill. $ -14.900 mill. 22 mill. - Y/Y -7.77 %
Market Cap. Revenues TTM Net Income TTM

$ 20.795 mill.


$ 1.049 mill.


$ -14.900 mill.

Employees Shares Outstanding P/E

-


22 mill.


-

Revenue Growth Income Growth

MRQ Y/Y -7.77 %


MRQ Y/Y - %



PETV

$0.55

$-0.4500 -45.00%
This Quarter Q2 of 2024


PETV

$0.55

$-0.4500 -45.00%



Petvivo Holdings Inc

Petvivo Holdings Inc shares went down -45.00% during this current quarter q2 of 2024.


PetVivo Holdings Inc*s business model revolves around developing and commercializing innovative medical devices that benefit pets.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 7.849 mill. $ 1.046 mill. $ -10.634 mill. 14 mill. - Y/Y 16.82 %
Market Cap. Revenues TTM Net Income TTM

$ 7.849 mill.


$ 1.046 mill.


$ -10.634 mill.

Employees Shares Outstanding P/E

4


14 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 16.82 %


MRQ Y/Y - %



EYE

$12.98

$-10.3900 -44.46%
This Quarter Q2 of 2024


EYE

$12.98

$-10.3900 -44.46%



National Vision Holdings Inc

National Vision Holdings Inc stock dropped -44.46% during this current quarter q2 of 2024.


National Vision Holdings Inc is a leading retailer of eyewear and optical products in the United States. The company operates a vertically integrated business model, which involves manufacturing, marketing, and distributing a wide range of eyewear products through its branded retail stores and third-party retail locations. National Vision Holdings Inc focuses on offering affordable and accessible vision care solutions to customers by leveraging its supply chain and retail network capabilities.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 1,023.161 mill. $ 2,106.622 mill. $ -72.486 mill. 79 mill. - Y/Y -3.53 %
Market Cap. Revenues TTM Net Income TTM

$ 1,023.161 mill.


$ 2,106.622 mill.


$ -72.486 mill.

Employees Shares Outstanding P/E

13,800


79 mill.


-

Revenue Growth Income Growth

MRQ Y/Y -3.53 %


MRQ Y/Y -36.04 %



PXDT

$1.53

$-1.1900 -43.75%
This Quarter Q2 of 2024


PXDT

$1.53

$-1.1900 -43.75%



Pixie Dust Technologies Inc

Pixie Dust Technologies Inc shares declined -43.75% during this current quarter q2 of 2024.


Pixie Dust Technologies Inc is a software development company that follows a B2B model, offering customized software solutions to businesses in various industries. They generate revenue by providing software development services, licensing their software products, and offering ongoing support and maintenance to their clients.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 10.360 mill. $ 5.182 mill. $ -14.453 mill. 7 mill. - Y/Y 0.00 %
Market Cap. Revenues TTM Net Income TTM

$ 10.360 mill.


$ 5.182 mill.


$ -14.453 mill.

Employees Shares Outstanding P/E

-


7 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 0.00 %


MRQ Y/Y - %



BBLG

$1.49

$-1.0800 -42.02%
This Quarter Q2 of 2024


BBLG

$1.49

$-1.0800 -42.02%



Bone Biologics Corporation

Bone Biologics Corporation shares declined -42.02% during this current quarter q2 of 2024.


Bone Biologics Corporation is a biotech company that focuses on the development and commercialization of innovative orthobiologic products to enhance bone healing. Their business model revolves around conducting research, developing proprietary technologies, and partnering with medical device companies to bring their products to market.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 0.985 mill. $ - mill. $ -7.233 mill. 1 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 0.985 mill.


$ - mill.


$ -7.233 mill.

Employees Shares Outstanding P/E

-


1 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



NMRD

$0.045

$-0.0320 -41.56%
This Quarter Q2 of 2024


NMRD

$0.045

$-0.0320 -41.56%



Nemaura Medical Inc

Nemaura Medical Inc stock dropped -41.56% during this current quarter q2 of 2024.


Nemaura Medical Inc*s business model revolves around developing innovative and cost-effective medical technologies and devices.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ - mill. $ - mill. $ -10.651 mill. - mill. 0.12 Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ - mill.


$ - mill.


$ -10.651 mill.

Employees Shares Outstanding P/E

-


- mill.


0.12

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



STVN

$17.54

$-12.3300 -41.28%
This Quarter Q2 of 2024


STVN

$17.54

$-12.3300 -41.28%



Stevanato Group S p a

Stevanato Group S P A shares dropped -41.28% during this current quarter q2 of 2024.


Stevanato Group S.p.a is a global provider of packaging and drug delivery solutions for the pharmaceutical industry. The company specializes in the design and manufacturing of glass containers, syringes, cartridges, and other primary packaging components. They also offer comprehensive services including drug delivery devices and analytical testing, ensuring end-to-end support for pharmaceutical companies.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 4,639.947 mill. $ 1,101.722 mill. $ 160.178 mill. 265 mill. 29.00 Y/Y 0.00 %
Market Cap. Revenues TTM Net Income TTM

$ 4,639.947 mill.


$ 1,101.722 mill.


$ 160.178 mill.

Employees Shares Outstanding P/E

-


265 mill.


29.00

Revenue Growth Income Growth

MRQ Y/Y 0.00 %


MRQ Y/Y 0.00 %



LUCD

$0.7219

$-0.4981 -40.83%
This Quarter Q2 of 2024


LUCD

$0.7219

$-0.4981 -40.83%



Lucid Diagnostics Inc

Lucid Diagnostics Inc shares declined -40.83% during this current quarter q2 of 2024.


Lucid Diagnostics Inc is a healthcare company that operates with a business model focused on developing and providing innovative diagnostic solutions for the early detection and prevention of diseases, aimed at improving patient outcomes and reducing healthcare costs. They leverage advanced technologies and medical expertise to deliver accurate and reliable diagnostic services to healthcare providers, enabling better decision-making and personalized treatment plans for patients.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 32.496 mill. $ 2.983 mill. $ -47.031 mill. 45 mill. - Y/Y 124.44 %
Market Cap. Revenues TTM Net Income TTM

$ 32.496 mill.


$ 2.983 mill.


$ -47.031 mill.

Employees Shares Outstanding P/E

-


45 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 124.44 %


MRQ Y/Y - %




 1 Day   Week  Current Month of June  30 Days 
Current Quarter Q2 of 2024  90 Days    Ytd    12 Months 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com